CX803 / Helixmith - LARVOL DELTA

Helixsmith "The speed of development of the follow-up pipeline of Engensys… Preparation for clinical trials such as CAR-T treatment" [Google translation] (Newspim) - "The subsidiary, Catexel, owns CX803, CX804, and CX805, which are chimeric antigen receptor (CAR-T) gene cell therapies. Catexel is a subsidiary of Helixsmith...Catexel will start the phase 1 clinical trial of CX804 for the treatment of neuroblastoma and ovarian cancer in 2023. Next year, it plans to apply for clinical plan approval (IND). Phase 1 clinical trials of CX803 for pancreatic cancer are also being prepared with the goal of starting in 2024."

IND • New P1 trial • Gastrointestinal Cancer • Gynecologic Cancers • Neuroblastoma • Oncology • Ovarian Cancer • Pancreatic Cancer